Y-mAbs Therapeutics, Inc. is a biopharmaceutical company that is focused on the development and commercialization of unique antibody-based therapeutic products for the treatment of cancer in the United States. The company's flagship product, DANYELZA, is a monoclonal antibody that is used in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is currently in the process of developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma, with the product currently in Phase II clinical study. In addition, Y-mAbs is also developing GD2-SADA, which is currently in a Phase I clinical trial for the treatment of GD2 positive solid tumors. Omburtamab is another candidate in Y-mAbs' pipeline, with the murine monoclonal antibody having completed pivotal Phase 2 clinical trials for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. The company is also currently in Phase 1 clinical trials for Omburtamab 03-133, which is intended for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. Another product in Y-mAbs' pipeline is huB7-H3, currently in development for the treatment of systemic solid tumors. The company has a license agreement in place with both Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology, which allows for the development and commercialization of licensed products. With its headquarters located in New York, New York, Y-mAbs Therapeutics, Inc. was founded in 2015 and has since become a commercial-stage biopharmaceutical company that is leading the way in unique antibody-based therapeutic products for cancer treatment.
Y-mAbs Therapeutics Inc's ticker is YMAB
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 51-200 employees working at Y-mAbs Therapeutics Inc
It is ymabs.com
Y-mAbs Therapeutics Inc is in the Healthcare sector
Y-mAbs Therapeutics Inc is in the Biotechnology industry
The following five companies are Y-mAbs Therapeutics Inc's industry peers: